-
公开(公告)号：US20050222160A1
公开(公告)日：2005-10-06
申请号：US10518503
申请日：2003-04-28
IPC分类号： A61K31/501 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/00 , A61P7/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/02 , A61P11/06 , A61P11/08 , A61P13/08 , A61P13/12 , A61P17/00 , A61P17/02 , A61P17/04 , A61P17/06 , A61P19/02 , A61P19/06 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/24 , A61P25/28 , A61P27/02 , A61P27/14 , A61P29/00 , A61P31/04 , A61P31/10 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22 , A61P33/02 , A61P33/06 , A61P35/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07D417/06 , C07D417/14 , C07D43/02
CPC分类号： C07D417/06 , C07D417/14
摘要： Thiazole derivatives of the formula I in which R1, R2, R3, V, W, X and B are as defined in claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
摘要翻译： 其中R 1，R 2，R 3，V，W，X和B的式I的噻唑衍生物如权利要求书中所定义， 1，作为磷酸二酯酶IV抑制剂，可用于治疗骨质疏松症，肿瘤，恶病质，动脉粥样硬化，类风湿性关节炎，多发性硬化，糖尿病，炎症过程，过敏，哮喘，自身免疫性疾病，心肌疾病和艾滋病。
-
公开(公告)号：US06884800B1
公开(公告)日：2005-04-26
申请号：US10129629
申请日：2000-10-31
IPC分类号： A61K31/5383 , A61K31/542 , A61P1/04 , A61P3/10 , A61P7/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/10 , A61P25/00 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/18 , A61P35/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D498/06 , C07D513/06 , A61K31/538 , A61K31/5415 , C07D413/02 , C07D417/02
CPC分类号： C07D513/06
摘要： Imidazole compounds of the formula I in which R1 and R2, independently of one another, each denote A1, OA1, SA1 or Hal, A1 denotes H, A, alkenyl, cycloalkyl or alkylenecycloalkyl, A denotes alkyl having 1-10 carbon atoms, Hal denotes F, Cl, Br or I, and X denotes O, S, SO or SO2, and their physiologically acceptable salts and/or solvates, as phosphodiesterase VII inhibitors, and their use for the preparation of a medicament.
摘要翻译： 其中R 1和R 2彼此独立的式I的咪唑化合物各自表示A 1，A 1， 或者Hal，A 1表示H，A，链烯基，环烷基或亚烷基环烷基，A表示具有1-10个碳原子的烷基，Hal表示F ，Cl，Br或I，X表示O，S，SO或SO 2，以及它们的生理学上可接受的盐和/或溶剂化物，作为磷酸二酯酶VII抑制剂，及其用于制备药物 。
-
![Pyrazolo [4,3-d]pyrimidines](/abs-image/US/2004/08/17/US06777419B1/abs.jpg.150x150.jpg)
公开(公告)号：US06777419B1
公开(公告)日：2004-08-17
申请号：US10070305
申请日：2002-07-29
IPC分类号： C07D48704
CPC分类号： C07D487/04
摘要： Pyrazolo[4,3-d]pyrimidines of the formula I and their physiologically acceptable salts, in which R1, R2, R3, R4 and X have the meanings indicated in Claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of disorders of the cardiovascular system and for the treatment and/or therapy of potency disorders.
摘要翻译： 式I的吡唑并[4,3-d]嘧啶及其生理上可接受的盐，其中R 1，R 2，R 3，R 4和X具有权利要求1所示的含义，表示磷酸二酯酶 V抑制，可用于治疗心血管系统疾病和治疗和/或治疗效力障碍。
-
44.发明授权公开(公告)号：US06531498B1
公开(公告)日：2003-03-11
申请号：US10129270
申请日：2002-05-03
IPC分类号： C07D26106
CPC分类号： A61K31/42
摘要： The invention relates to compounds of formula I and to their physiologically acceptable salts and solvates which act as phosphodiesterse VII inhibitors and are thus useful for the treatment of allergic disorders, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin disorders, inflammatory disorders, autoimmune diseases, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumor growth, tumor metastases, sepsis, memory disturbances, atherosclerosis and AIDS.
摘要翻译： 本发明涉及式I化合物及其作为磷酸二酯VII抑制剂的生理上可接受的盐和溶剂合物，因此可用于治疗过敏性疾病，哮喘，慢性支气管炎，特应性皮炎，牛皮癣和其他皮肤病，炎症性疾病， 自身免疫疾病，类风湿性关节炎，多发性硬化，克罗恩病，糖尿病或溃疡性结肠炎，骨质疏松症，移植排斥反应，恶病质，肿瘤生长，肿瘤转移，败血症，记忆障碍，动脉粥样硬化和艾滋病。
-
公开(公告)号：US09273029B2
公开(公告)日：2016-03-01
申请号：US14118845
申请日：2012-04-11
IPC分类号： C07D401/12 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D471/04 , C07D491/048 , C07D409/04
CPC分类号： C07D401/12 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D405/14 , C07D409/04 , C07D409/14 , C07D471/04 , C07D491/048
摘要： Compounds of the formula (I) in which R, R1 and X have the meanings indicated in claim 1, are inhibitors of TBK1 and IKKε and can be employed, inter alia, for the treatment of cancer and inflammatory diseases
摘要翻译： 其中R，R 1和X具有权利要求1所示含义的式（I）化合物是TBK1和IKK的抑制剂; 并且可以用于治疗癌症和炎性疾病
-
公开(公告)号：US08546565B2
公开(公告)日：2013-10-01
申请号：US13133495
申请日：2009-11-12
IPC分类号： C07D239/70 , A01N43/54
CPC分类号： C07D403/12 , C07D403/06 , C07D403/14
摘要： Novel quinazolinamide derivatives of the formula (I), in which R1-R5 and X have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
摘要翻译： 式（I）的新型喹唑啉酰胺衍生物，其中R1-R5和X具有权利要求1所述的含义，是HSP90抑制剂，可用于制备用于治疗其中抑制，调节和 /或HSP90调节起作用。
-
公开(公告)号：US08119795B2
公开(公告)日：2012-02-21
申请号：US12301140
申请日：2007-04-20
IPC分类号： A61K31/4196 , C07D503/12 , C07D249/12 , C07D401/12
CPC分类号： C07D249/08 , C07D401/12 , C07D403/12
摘要： Novel triazole derivatives of the formula (I) in which R1-R6 and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
摘要翻译： 式（I）的新型三唑衍生物，其中R 1 -R 6和Y具有权利要求1所述的含义，是HSP90抑制剂，可用于制备用于治疗其中抑制，调节和/ 或调制HSP90起作用。
-
公开(公告)号：US07977343B2
公开(公告)日：2011-07-12
申请号：US12063384
申请日：2006-07-20
IPC分类号： A61K31/535
CPC分类号： C07D473/34
摘要： Novel adenine derivatives of the formula (I), in which R1, R2, R3, X and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
摘要翻译： 式（I）的新型腺嘌呤衍生物，其中R 1，R 2，R 3，X和Y具有权利要求1所示的含义，是HSP90抑制剂，可用于制备用于治疗疾病的药物 HSP90的抑制，调节和/或调节起着重要的作用。
-
49.发明授权2-amino-4-phenylquinazoline derivatives and the use thereof as HSP90 modulators 失效2-氨基-4-苯基喹唑啉衍生物及其作为HSP90调节剂的用途公开(公告)号：US07947696B2
公开(公告)日：2011-05-24
申请号：US11914604
申请日：2006-04-24
IPC分类号： A61K31/517
CPC分类号： C07D401/12 , C07D239/84 , C07D403/12
摘要： Novel phenylquinazoline derivatives of the formula (I), in which R1, R2, R3, R4 and R5 have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
摘要翻译： 式（I）的新的苯基喹唑啉衍生物，其中R 1，R 2，R 3，R 4和R 5具有权利要求1所示的含义，是HSP90抑制剂，可用于制备用于治疗疾病的药物 HSP90的抑制，调节和/或调节起着重要的作用。
-
公开(公告)号：US20100113542A1
公开(公告)日：2010-05-06
申请号：US12523387
申请日：2007-12-11
IPC分类号： A61K31/4196 , A61P31/12 , A61P35/00 , A61P37/00 , C07D249/08 , C07F9/06 , C07D249/12 , C07H17/02
CPC分类号： C07D249/12
摘要： 5-[4-(2-Methylphenyl)-3-hydroxy-4H-1,2,4-triazol-5-yl]-2,4-dihydroxy-N-methyl-N-butylbenzamide is an HSP90 inhibitor and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
摘要翻译： 5- [4-（2-甲基苯基）-3-羟基-4H-1,2,4-三唑-5-基] -2,4-二羟基-N-甲基-N-丁基苯甲酰胺是HSP90抑制剂，可以是 用于制备用于治疗其中HSP90的抑制，调节和/或调节起作用的疾病的药物的制备。
-
-
-
-
-
-
-
-
-
搜索结果
57 条记录 (耗时 0.032 秒)
